InvIOs GmbH | WebDisclosure

Basculer en Français

8295	Companies
114809	Keywords
55260	Articles
62422	Press releases

Home
Companies
InvIOs GmbH

BRIEF

published on 10/15/2024 at 10:35, 1 month 5 days ago

InvIOs Secures €8.2 Million Series A Funding for Immuno-oncology Innovations

Biotechnology Fundraising Clinical Trials Immuno-oncology InvIOs GmbH
BRIEF

published on 10/15/2024 at 10:35, 1 month 5 days ago

InvIOS obtient un financement de série A de 8,2 millions d'euros pour des innovations en immuno-oncologie

Biotechnologie Essais Cliniques Immuno-oncologie Collecte De Fonds InvIOs GmbH
PRESS RELEASE

published on 10/15/2024 at 10:30, 1 month 5 days ago

invIOs raises €8.2 million in a Series A to finance pipeline progress in immuno-oncology
invIOs GmbH raises €8.2 million in Series A funding to advance immuno-oncology pipeline progress through 2025, collaborating with Dana-Farber Cancer Institute

Series A Funding Immuno-oncology Pipeline Progress InvIOs Dana-Farber Cancer Institute
BRIEF

published on 07/17/2024 at 10:05, 4 months 3 days ago

InvIOs Selects INV501 Lead Candidate for IND-Enabling Studies in Glioblastoma and Melanoma

Cancer Therapy Melanoma Preclinical Studies INV501 Glioblastoma
BRIEF

published on 07/17/2024 at 10:05, 4 months 3 days ago

InvIOs sélectionne le candidat principal INV501 pour des études IND-habilitantes sur le glioblastome et le mélanome

Thérapie Contre Le Cancer Etudes Précliniques Mélanome INV501 Glioblastome
PRESS RELEASE

published on 07/17/2024 at 10:00, 4 months 3 days ago

invIOs selects INV501 lead candidate to progress into IND-enabling studies in glioblastoma and melanoma
invIOs selects INV501 lead candidate to progress into IND-enabling studies in glioblastoma and melanoma. The compound shows strong activation of tumor-specific T cells in preclinical testing

Melanoma IND-enabling Studies INV501 Glioblastoma InvIOs
PRESS RELEASE

published on 11/09/2023 at 11:30, 1 year ago

invIOs and Dana-Farber Cancer Institute start collaboration to study novel small molecule INV501 for treatment of glioblastoma
PRESS RELEASE

published on 09/05/2023 at 09:00, 1 year 2 months ago

invIOs starts further clinical trial of APN401, novel cell therapy against solid cancers, and secures major Austrian grant funding
PRESS RELEASE

published on 06/19/2023 at 14:30, 1 year 5 months ago

invIOs presents exciting preclinical data showing that immune-activating small molecule INV501 induces strong cytotoxic activity against solid tumors
PRESS RELEASE

published on 04/18/2023 at 15:00, 1 year 7 months ago

invIOs presents promising new clinical data in solid tumors from autologous cell therapy APN401 at AACR Annual Meeting 2023

Accesswire

Published on 11/21/2024 at 09:00, 35 minutes ago

ProScore Announces Domestic Content Solution for Inflation Reduction Act Requirements
Published on 11/21/2024 at 00:35, 9 hours ago

Vision Marine Technologies Establishes a Strategic Hub for Electric Boat Sales, Rentals, and Distribution, Marking a Milestone at Dania Pointe’s Grand Opening of Aileron Residences
Published on 11/21/2024 at 00:25, 9 hours 10 minutes ago

Biomind Labs Welcomes U.S. Policy Shift as a Historic Milestone for Psychedelic Therapies
Published on 11/21/2024 at 00:00, 9 hours 35 minutes ago

Swiss Mining Institute Conference Presentation
Published on 11/20/2024 at 23:00, 10 hours 35 minutes ago

Rektron Group Inc. Announces Appointment of a New Director and Provides Corporate Updates

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 09:01, 33 minutes ago

Original-Research: Netfonds AG (von NuWays AG): Buy
Published on 11/21/2024 at 08:59, 35 minutes ago

Black Friday Savings: Kling AI Offers 50% Off and Free Feature Upgrades
Published on 11/21/2024 at 08:59, 35 minutes ago

Économies Black Friday : Kling AI propose 50 % de réduction et des mises à niveau gratuites des fonctionnalités
Published on 11/21/2024 at 08:15, 1 hour 20 minutes ago

EBIT increases to EUR 55.6 million. Equity (net asset value) increases by EUR 49.3 million to EUR 300.3 million, which corresponds to 70.14 euros per share. The equity ratio rises to 94.85%.
Published on 11/21/2024 at 08:09, 1 hour 25 minutes ago

KAP HOLDS ITS GROUND IN A DIFFICULT INDUSTRY ENVIRONMENT IN THE FIRST NINE MONTHS OF 2024

Les Echos

Published on 11/21/2024 at 06:58, 2 hours 37 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 2 hours 37 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 2 hours 37 minutes ago

Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Published on 11/20/2024 at 20:07, 13 hours 27 minutes ago

Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Published on 11/20/2024 at 19:20, 14 hours 15 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting

View all LES ECHOS COMFI WIRE